Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2009 by Stanford University.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00482157
First received: May 31, 2007
Last updated: June 23, 2009
Last verified: June 2009

May 31, 2007
June 23, 2009
February 2007
November 2007   (final data collection date for primary outcome measure)
PSA velocity > than 2 ng/ml/year; any adverse pathological findings on extended pattern biopsies with a Gleason sum >7; involvement of > 50% of any core by cancer; > 1/3 of cores positive; or other incidental evidence of clinical progression
PSA velocity > than 2 ng/ml/year; any adverse pathological findings on extended pattern biopsies with a Gleason sum >7; involvement of > 50% of any core by cancer; > 1/3 of cores positive; or other incidental evidence of clinical progression [ Time Frame: within 12 months, visits at 2 weeks, 3 months, 6 months, 12 months ]
Complete list of historical versions of study NCT00482157 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance
Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance

After the diagnosis of prostate cancer, many men alter their lifestyle or diet or use various supplements in an attempt to retard the growth of their cancer. While there is limited data on the use of diet and supplements to alter the risk of prostate cancer, even less is known regarding the ability of diet or supplements to alter progression. For men who have elected active surveillance, the investigators propose to investigate the ability of vitamin D to retard the growth of prostate cancer.

Men will be randomized to each of two arms for a total of 24 subjects: calcitriol alone (DN101, 45 micrograms once weekly) or placebo. Baseline laboratory assays, including serum PSA, serum and urine calcium and creatinine, will be performed and the EPIC questionnaire (expanded prostate cancer index composite, validated HRQOL tool for prostate cancer patients) will be completed. Patients will also undergo prostate needle biopsy [4 cores taken under transrectal ultrasound (TRUS) guidance] to establish baseline levels of gene expression. Follow-up at the end of 2 weeks (just prior to the third dose) will include a history and physical, and a repeat of all baseline blood and urine tests. Follow-up at 3 months will include a history and physical, repeating all blood and urine tests, and the EPIC questionnaire. At 6 months, in addition to the history and physical, blood and urine tests, and the EPIC questionnaire, a TRUS-guided prostate needle biopsy will be performed. This will be a standard 12-core scheme and 4 of these cores will be used for laboratory analysis. Renal ultrasounds will again be performed on men in the calcitriol arms to look for stones. Patients who show no evidence of clinical progression will be offered to remain on study, in their designated treatment arm, for an additional 6 months. Any patient exhibiting clinical progression at any time will be withdrawn from the study and offered standard treatment options. For patients remaining on study at 12 months, an end-of-study biopsy will be requested (12-core scheme with 4 cores used for laboratory analysis)

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Prostatic Neoplasms
Drug: Vitamin D (Calcitriol)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
24
November 2008
November 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:- Untreated prostate adenocarcinoma by an extended biopsy (>8 needle cores on systematic prostate biopsy) within 1 year of the screening date

  • PSA <10.0 ng/ml
  • Gleason sum 6 or <2 mm Gleason pattern 4
  • No more than 33% of biopsy cores positive

Exclusion Criteria:- Prior or concurrent treatment for prostate cancer

  • Use of Finasteride, Dutasteride, Saw Palmetto
  • Use of NSAIDs, COX-2 inhibitors and/or aspirin, soy or vitamin D supplements for more than 7 days over the one month prior to study
  • Kidney disease, hypercalcemia or renal stones
  • ECOG performance status >1
  • Uncontrolled hypertension, unstable angina, history of transient ischemic attack (TIA), history of stroke.
Male
45 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00482157
PROS0022, 97408, PROS0022
Not Provided
Joseph C. Presti Jr., Principal Investigator, Stanford University School of Medicine
Stanford University
Not Provided
Principal Investigator: Joseph C. Presti Jr. Stanford University
Stanford University
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP